Novavax, Inc. (NASDAQ:NVAX – Get Rating)’s share price dropped 8% during trading on Tuesday . The stock traded as low as $50.73 and last traded at $50.77. Approximately 35,335 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 5,004,428 shares. The stock had previously closed at $55.16.
NVAX has been the topic of a number of recent analyst reports. Jefferies Financial Group initiated coverage on Novavax in a research report on Tuesday, February 22nd. They set a “buy” rating and a $198.00 target price on the stock. StockNews.com initiated coverage on Novavax in a research report on Thursday, March 31st. They set a “hold” rating on the stock. B. Riley decreased their target price on Novavax from $265.00 to $250.00 in a research report on Wednesday, March 2nd. Cantor Fitzgerald decreased their target price on Novavax from $282.00 to $174.00 and set an “overweight” rating on the stock in a research report on Monday, February 14th. Finally, HC Wainwright decreased their target price on Novavax from $294.00 to $207.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Novavax presently has an average rating of “Buy” and a consensus target price of $204.86.
The firm has a market capitalization of $4.21 billion, a price-to-earnings ratio of -2.19 and a beta of 1.34. The business has a 50 day simple moving average of $75.55 and a 200-day simple moving average of $124.95. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.90 and a current ratio of 0.90.
In related news, Director James F. Young sold 12,500 shares of the firm’s stock in a transaction dated Thursday, March 31st. The stock was sold at an average price of $73.58, for a total transaction of $919,750.00. Following the completion of the sale, the director now directly owns 62,590 shares of the company’s stock, valued at approximately $4,605,372.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. Spire Wealth Management increased its position in shares of Novavax by 186.7% during the 4th quarter. Spire Wealth Management now owns 172 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 112 shares during the last quarter. Selective Wealth Management Inc. acquired a new stake in shares of Novavax during the 4th quarter worth about $29,000. DB Wealth Management Group LLC acquired a new position in Novavax in the 4th quarter valued at about $29,000. FUKOKU MUTUAL LIFE INSURANCE Co grew its position in Novavax by 40.0% in the 3rd quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 280 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 80 shares in the last quarter. Finally, TCI Wealth Advisors Inc. grew its position in Novavax by 115.7% in the 4th quarter. TCI Wealth Advisors Inc. now owns 289 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 155 shares in the last quarter. 47.38% of the stock is owned by hedge funds and other institutional investors.
Novavax Company Profile (NASDAQ:NVAX)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.